Antibody response to inactivated COVID-19 vaccine (CoronaVac) in immune-mediated diseases: a controlled study among hospital workers and elderly

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

(2021) Denis Y Logunov et al.   LANCET

SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases

(2021) David Simon et al.   ANNALS OF THE RHEUMATIC DISEASES

Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort

(2021) Ulf M Geisen et al.   ANNALS OF THE RHEUMATIC DISEASES

Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients

(2021) Brian J. Boyarsky et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients

(2021) Liane Rabinowich et al.   JOURNAL OF HEPATOLOGY

American College of Rheumatology Guidance for COVID‐19 Vaccination in Patients with Rheumatic and Musculoskeletal Diseases – Version 1

(2021) Jeffrey R Curtis et al.   Arthritis & Rheumatology

Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease

(2021) Rebecca H Haberman et al.   ANNALS OF THE RHEUMATIC DISEASES

Weak anti–SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients

(2021) Ilies Benotmane et al.   KIDNEY INTERNATIONAL

Development of an inactivated vaccine candidate for SARS-CoV-2

(2020) Qiang Gao et al.   SCIENCE

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

(2020) Fernando P. Polack et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

(2020) Yanjun Zhang et al.   LANCET INFECTIOUS DISEASES

Effects of biological and non-biological immunomodulatory therapies on the immunogenicity of vaccines in patients with rheumatic diseases

(2014) Zsuzsanna H McMahan et al.   ARTHRITIS RESEARCH & THERAPY

Age Affects Quantity but Not Quality of Antibody Responses after Vaccination with an Inactivated Flavivirus Vaccine against Tick-Borne Encephalitis

(2012) Karin Stiasny et al.   PLoS One

Immunization responses in rheumatoid arthritis patients treated with rituximab: Results from a controlled clinical trial

(2009) Clifton O. Bingham et al.   ARTHRITIS AND RHEUMATISM